Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 2011

View Archived Issues

Phase II trial investigates SPD-503 in new indication

Genmab achieves milestone in collaboration with Lundbeck

Putative biomarker in non-cystic fibrosis bronchiectasis identified

Scientists at AstraZeneca present new therapy for AML

Malaria vaccine is safe and immunogenic in phase Ib study

Dual dopamine D2 receptor/NET inhibitors identified by Astellas Pharma

Novel glucocorticoid receptor agonist shows anti-inflammatory activity

New dipeptidyl peptidase 4 inhibitors patented by Chinese company

Novel p140-TrkA inhibitors prepared by Array BioPharma

Scientists at Mitsubishi Tanabe Pharma disclose new GPR119 receptor agonists

Abilify approved in Canada for use in new patient population

Dainippon Sumitomo Pharma presents novel amide derivatives

Merck & Co. synthesizes new PRCP inhibitors

Merck & Co. and Roche begin clinical collaboration for HCV infection

Phase II AX-200 study does not meet endpoints

Galapagos announces proof-of-mechanism milestone in alliance with GSK

Phase III study begins for ALKS-9070

New fenofibrate products launched in Japan for hyperlipidemia

Pharmasset to amend design of phase IIb PSI-938 trial

FDA approves Advate for new indication

CHMP issues recommendation on marketing authorization Esmya

Roche's Zelboraf receives CHMP opinion

ISTA Pharmaceuticals declines Valeant's acquisition offer

LabCorp acquires Orchid Cellmark

Zalicus begins phase I Z-944 study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...